Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1…
-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell…
Read More...
Read More...
Browsing Tag
Caribou Biosciences
Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
<!-- Name:DistributionId Value:8784488 -->
<!--…
Read More...
Read More...
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA…
-- CaMMouflage Phase 1 clinical trial to initiate patient enrollment at dose level 1 in early 2023 -- -- CB-011 is…
Read More...
Read More...
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading…
Read More...
Read More...
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1…
BERKELEY, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading…
Read More...
Read More...
Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology…
BERKELEY, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading…
Read More...
Read More...
Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors
BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading…
Read More...
Read More...
Caribou Biosciences to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading…
Read More...
Read More...
Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with…
Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key…
Read More...
Read More...